We are live on ! Find out more
NVO

Novo Nordisk

552 hedge funds and large institutions have $8.82B invested in Novo Nordisk in 2017 Q4 according to their latest regulatory filings, with 104 funds opening new positions, 144 increasing their positions, 173 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more first-time investments, than exits

New positions opened: 104 | Existing positions closed: 41

70% more call options, than puts

Call options by funds: $42.7M | Put options by funds: $25.1M

16% more capital invested

Capital invested by funds: $7.6B → $8.82B (+$1.23B)

12% more funds holding

Funds holding: 491552 (+61)

12% more funds holding in top 10

Funds holding in top 10: 1719 (+2)

0.67% more ownership

Funds ownership: 16.09%16.76% (+0.67%)

17% less repeat investments, than reductions

Existing positions increased: 144 | Existing positions reduced: 173

Holders
552
Holders Change
+61
Holders Change %
+12.42%
% of All Funds
12.52%
Holding in Top 10
19
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+11.76%
% of All Funds
0.43%
New
104
Increased
144
Reduced
173
Closed
41
Calls
$42.7M
Puts
$25.1M
Net Calls
+$17.6M
Net Calls Change
+$5.51M

NVO Hedge Fund Activity: Q4 2017 in Review

552 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2017, worth a combined $8.82B — up 16% from $7.6B a quarter earlier.

Buyers outnumbered sellers: 104 funds opened new NVO positions and 41 closed out — a net gain of 63 holders — while 144 added to existing stakes and 173 trimmed.

The largest buyer was BlackRock, adding an estimated $371M. The largest seller was Bank of America, cutting an estimated $92.9M.

  • 552 institutional investors held Novo Nordisk (NVO) as of Q4 2017, up from 491 in Q3 2017.
  • Funds reported $8.82B of Novo Nordisk stock for Q4 2017, up 16% quarter-over-quarter.
  • 104 funds opened new Novo Nordisk positions in Q4 2017 and 41 closed out, a net change of +63 holders.
  • The largest Novo Nordisk buyer in Q4 2017 was BlackRock, an estimated $371M added.
  • The largest Novo Nordisk seller in Q4 2017 was Bank of America, an estimated $92.9M sold.

Based on aggregated 13F filings for Q4 2017.